Aurinia Pharmaceuticals (NASDAQ:AUPH) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Royal Bank Of Canada boosted their price objective on Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Monday, November 2nd. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. TD Cowen increased their target price on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Aurinia Pharmaceuticals Price Performance

Shares of Aurinia Pharmaceuticals stock opened at $16.62 on Friday. The company has a quick ratio of 4.97, a current ratio of 6.12 and a debt-to-equity ratio of 0.06. Aurinia Pharmaceuticals has a twelve month low of $13.52 and a twelve month high of $19.25. The business has a 50-day moving average price of $16.48 and a 200 day moving average price of $15.69. The firm has a market cap of $2.23 billion, a PE ratio of 16.77 and a beta of 1.40.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Friday, October 30th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The company had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $83.61 million. Aurinia Pharmaceuticals had a return on equity of 22.99% and a net margin of 97.68%. Sell-side analysts predict that Aurinia Pharmaceuticals will post 0.97 earnings per share for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

Large investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $3,820,000. Legal & General Group Plc purchased a new position in Aurinia Pharmaceuticals during the second quarter worth approximately $1,747,000. OMERS ADMINISTRATION Corp purchased a new position in Aurinia Pharmaceuticals during the second quarter worth approximately $1,573,000. Man Group plc acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $1,424,000. Finally, PDT Partners LLC acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $4,505,000. 36.83% of the stock is currently owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs.

Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy.

Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.